Cargando…
Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I)
BACKGROUND: Treatment plans for squamous cell carcinoma of the head and neck (SCCHN) are individually decided in tumor board meetings but some treatment decision-steps lack objective prognostic estimates. Our purpose was to explore the potential of radiomics for SCCHN therapy-specific survival progn...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236822/ https://www.ncbi.nlm.nih.gov/pubmed/37268876 http://dx.doi.org/10.1186/s12880-023-01034-1 |
_version_ | 1785053026778611712 |
---|---|
author | Bernatz, Simon Böth, Ines Ackermann, Jörg Burck, Iris Mahmoudi, Scherwin Lenga, Lukas Martin, Simon S. Scholtz, Jan-Erik Koch, Vitali Grünewald, Leon D. Koch, Ina Stöver, Timo Wild, Peter J. Winkelmann, Ria Vogl, Thomas J. dos Santos, Daniel Pinto |
author_facet | Bernatz, Simon Böth, Ines Ackermann, Jörg Burck, Iris Mahmoudi, Scherwin Lenga, Lukas Martin, Simon S. Scholtz, Jan-Erik Koch, Vitali Grünewald, Leon D. Koch, Ina Stöver, Timo Wild, Peter J. Winkelmann, Ria Vogl, Thomas J. dos Santos, Daniel Pinto |
author_sort | Bernatz, Simon |
collection | PubMed |
description | BACKGROUND: Treatment plans for squamous cell carcinoma of the head and neck (SCCHN) are individually decided in tumor board meetings but some treatment decision-steps lack objective prognostic estimates. Our purpose was to explore the potential of radiomics for SCCHN therapy-specific survival prognostication and to increase the models’ interpretability by ranking the features based on their predictive importance. METHODS: We included 157 SCCHN patients (male, 119; female, 38; mean age, 64.39 ± 10.71 years) with baseline head and neck CT between 09/2014 and 08/2020 in this retrospective study. Patients were stratified according to their treatment. Using independent training and test datasets with cross-validation and 100 iterations, we identified, ranked and inter-correlated prognostic signatures using elastic net (EN) and random survival forest (RSF). We benchmarked the models against clinical parameters. Inter-reader variation was analyzed using intraclass-correlation coefficients (ICC). RESULTS: EN and RSF achieved top prognostication performances of AUC = 0.795 (95% CI 0.767–0.822) and AUC = 0.811 (95% CI 0.782–0.839). RSF prognostication slightly outperformed the EN for the complete (ΔAUC 0.035, p = 0.002) and radiochemotherapy (ΔAUC 0.092, p < 0.001) cohort. RSF was superior to most clinical benchmarking (p ≤ 0.006). The inter-reader correlation was moderate or high for all features classes (ICC ≥ 0.77 (± 0.19)). Shape features had the highest prognostic importance, followed by texture features. CONCLUSIONS: EN and RSF built on radiomics features may be used for survival prognostication. The prognostically leading features may vary between treatment subgroups. This warrants further validation to potentially aid clinical treatment decision making in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12880-023-01034-1. |
format | Online Article Text |
id | pubmed-10236822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102368222023-06-03 Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I) Bernatz, Simon Böth, Ines Ackermann, Jörg Burck, Iris Mahmoudi, Scherwin Lenga, Lukas Martin, Simon S. Scholtz, Jan-Erik Koch, Vitali Grünewald, Leon D. Koch, Ina Stöver, Timo Wild, Peter J. Winkelmann, Ria Vogl, Thomas J. dos Santos, Daniel Pinto BMC Med Imaging Research BACKGROUND: Treatment plans for squamous cell carcinoma of the head and neck (SCCHN) are individually decided in tumor board meetings but some treatment decision-steps lack objective prognostic estimates. Our purpose was to explore the potential of radiomics for SCCHN therapy-specific survival prognostication and to increase the models’ interpretability by ranking the features based on their predictive importance. METHODS: We included 157 SCCHN patients (male, 119; female, 38; mean age, 64.39 ± 10.71 years) with baseline head and neck CT between 09/2014 and 08/2020 in this retrospective study. Patients were stratified according to their treatment. Using independent training and test datasets with cross-validation and 100 iterations, we identified, ranked and inter-correlated prognostic signatures using elastic net (EN) and random survival forest (RSF). We benchmarked the models against clinical parameters. Inter-reader variation was analyzed using intraclass-correlation coefficients (ICC). RESULTS: EN and RSF achieved top prognostication performances of AUC = 0.795 (95% CI 0.767–0.822) and AUC = 0.811 (95% CI 0.782–0.839). RSF prognostication slightly outperformed the EN for the complete (ΔAUC 0.035, p = 0.002) and radiochemotherapy (ΔAUC 0.092, p < 0.001) cohort. RSF was superior to most clinical benchmarking (p ≤ 0.006). The inter-reader correlation was moderate or high for all features classes (ICC ≥ 0.77 (± 0.19)). Shape features had the highest prognostic importance, followed by texture features. CONCLUSIONS: EN and RSF built on radiomics features may be used for survival prognostication. The prognostically leading features may vary between treatment subgroups. This warrants further validation to potentially aid clinical treatment decision making in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12880-023-01034-1. BioMed Central 2023-06-02 /pmc/articles/PMC10236822/ /pubmed/37268876 http://dx.doi.org/10.1186/s12880-023-01034-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bernatz, Simon Böth, Ines Ackermann, Jörg Burck, Iris Mahmoudi, Scherwin Lenga, Lukas Martin, Simon S. Scholtz, Jan-Erik Koch, Vitali Grünewald, Leon D. Koch, Ina Stöver, Timo Wild, Peter J. Winkelmann, Ria Vogl, Thomas J. dos Santos, Daniel Pinto Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I) |
title | Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I) |
title_full | Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I) |
title_fullStr | Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I) |
title_full_unstemmed | Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I) |
title_short | Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I) |
title_sort | radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part i) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236822/ https://www.ncbi.nlm.nih.gov/pubmed/37268876 http://dx.doi.org/10.1186/s12880-023-01034-1 |
work_keys_str_mv | AT bernatzsimon radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT bothines radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT ackermannjorg radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT burckiris radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT mahmoudischerwin radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT lengalukas radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT martinsimons radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT scholtzjanerik radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT kochvitali radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT grunewaldleond radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT kochina radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT stovertimo radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT wildpeterj radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT winkelmannria radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT voglthomasj radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti AT dossantosdanielpinto radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti |